Form 4: Pacira BioSciences COO Daryl Gaugler Reports Stock Transactions

Chief Operating Officer of Pacira BioSciences, Daryl Gaugler, reports acquisition of restricted stock units and sale of common stock.

Summary

• Daryl Gaugler, the Chief Operating Officer of Pacira BioSciences, filed a Form 4 detailing changes in beneficial ownership.
• On June 12, 2024, Gaugler acquired 54,300 restricted stock units (RSUs) at a price of $0.
• These RSUs vest in four equal annual installments starting June 3, 2025, contingent upon continuous service with the issuer.
• Each RSU represents the right to receive one share of Pacira BioSciences common stock.
• On June 13, 2024, Gaugler sold 1,000 shares of common stock at a price of $28.38 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Gaugler beneficially owns 116,039.584 shares of Pacira BioSciences common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects routine transactions by a company executive. The acquisition of RSUs is a positive sign, while the sale of shares is not necessarily negative given the pre-arranged trading plan.

Positives

• The acquisition of restricted stock units aligns Gaugler's interests with the long-term performance of Pacira BioSciences.
• The vesting schedule of the RSUs incentivizes continued service with the company.

Negatives

• The sale of 1,000 shares could be interpreted negatively, although it was conducted under a pre-arranged trading plan.

Risks

• The value of the restricted stock units is contingent on Gaugler's continued employment with Pacira BioSciences.
• The stock price could fluctuate, affecting the value of the shares held by Gaugler.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs implies an expectation of continued service and contribution from the COO.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their trading activities. The use of a 10b5-1 plan suggests a planned and orderly approach to stock sales.

Comparison to Industry Standards

• Comparing Gaugler's transactions to those of executives at similar-sized biotech companies like BioCryst Pharmaceuticals or Eagle Pharmaceuticals shows similar patterns of stock option exercises and sales for diversification or tax planning.
• The use of Rule 10b5-1 trading plans is a common practice among corporate executives to avoid accusations of insider trading, aligning with industry best practices.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, providing transparency into executive compensation and trading activity.
• Employees may view the RSU grants as a positive sign of the company's commitment to its executives.

Key Dates